乳腺癌个体化综合治疗的临床疗效分析

Curative effectiveness analysis on combined-therapy strategy for breast cancer

目的探讨乳腺癌综合治疗模式的临床运行效果。方法回顾性分析德阳市人民医院从2009年1月至2012年12月收治的300例乳腺癌患者的病历资料,比较综合治疗模式与非综合治疗模式的临床治疗效果。结果综合治疗组总有效率明显高于非综合治疗组(P<0.05);术后早期并发症方面,综合治疗组术后皮下积液、患侧上肢水肿、皮瓣坏死的发生率均显著低于非综合治疗组(P<0.05);不良反应方面,除乏力、手足口综合症发生率两组间无明显差异外(P>0.05),综合治疗组胃肠道反应、白细胞减少、外周神经毒性、血红蛋白和血小板降低、黏膜炎、皮疹发生率显著低于非综合治疗组(P<0.05)。综合治疗组的患者术后肿瘤复发率、转移率均显著低于非综合治疗组(P<0.05),综合治疗组的患者术后总生存时间以及无病生存时间均显著高于非综合治疗组(P<0.05)。结论在乳腺癌的治疗中,综合治疗合理分配了治疗方案中各科时间,治疗效果好,可以显著地降低术后早期并发症的发生率和肿瘤复发率。

Objective To explore the clinical performance of combined-therapy for breast cancer. Methods To compare the therapeutic effectiveness between combined-therapy and non-combined-therapy groups by retrospectively analyzing the data of 300 patients who diagnosed as breast cancer and accepted in-hospital therapy from January 2009 to December 2012. Results The effectiveness rate in combined-therapy group was higher than that in non-combined-therapy group （P〈0.05）. As early postoperative complications, the incidence of subcutaneous effusion, edema of the upper limb, flap necrosis in combined-therapy group was lower than that in non-combined-therapy group （P〈0.05）. To compared with non- combined-therapy group, the incidence of side effects included leukopenia, malaise, gastrointestinal discomfort, hemoglobin decrease and thrombocytopenia, neurotoxicity, and mucositis in combined-therapy group was significantly lower （P〈0.05）. During the follow-up, less cancer recurrence rate and longer median survival time happened in the combined-therapy group （P〈0.05）. Conclusion The combined-therapy strategy for breast cancer treatment has reasonable time for therapy and more satisfied surgical outcomes, and reduced the incidence of early complications and tumor recurrence.